Clinical trial
Pemetrexed Disodium and Gemcitabine in Treating Patients With Stage IIIB or…
NCT00407550 · Mayo Clinic, Other · Completed
Key facts
| NCT number | NCT00407550 |
|---|---|
| Title | Pemetrexed Disodium and Gemcitabine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer |
| Official title | A Randomized Phase II Study of ALIMTA® (Pemetrexed) and GEMZAR® (Gemcitabine) Every 14 Days Versus Pemetrexed and Gemcitabine Every 21 Days in Advanced Non-Small Cell Lung Cancer |
| Lead sponsor | Mayo Clinic, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug |
| Interventions | gemcitabine HCL, pemetrexed disodium |
| Enrollment | 19 |
| Start date | Nov 1, 2006 |
| Primary completion | Jan 1, 2008 |
| Completion | May 12, 2010 |
| First posted | Dec 5, 2006 |
| Last update posted | May 2, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: